00:39 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Mouse studies suggest mesenchymal stem cell (MSC)-derived vesicles loaded with a CXCR3 inhibitor could help treat pancreatic cancer. The vesicles are derived via sonication from the membranes of tumor-targeting primary human bone...
08:00 , Jan 22, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CXC chemokine receptor 3 (CXCR3)

Neurology INDICATION: Alzheimer's disease (AD) In vitro and mouse studies suggest antagonizing CXCR3 could help treat AD. In the mouse amyloid precursor protein (APP) / presenilin 1 ( PSEN1 ; PS1 ) model of AD,...
07:00 , Mar 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease Chemokine CXC motif ligand 10 (CXCL10; IP-10); CXC chemokine receptor 3 (CXCR3) Human sample and mouse studies suggest inhibiting CXCL10 could help...
07:00 , Nov 1, 2012 |  BC Innovations  |  Targets & Mechanisms

Prime and pull against HSV-2

Yale School of Medicine researchers have mouse data showing that vaginal application of two chemokines recruits memory T cells into vaginal tissue and improves the protective effect of an HSV-2 vaccine . 1 The team...
07:00 , Aug 4, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Imaging

Approach Summary Licensing status Publication and contact information Imaging Noninvasive, live imaging of immune responses Noninvasive, real-time imaging of immune responses could help evaluate transplant outcomes and response to therapy. In immunocompetent mice with GFP-labeled...
07:00 , Jun 3, 2010 |  BC Innovations  |  Targets & Mechanisms

A new angle in fibrosis

The cytokine CXCL10 has been shown to reduce lung fibrosis, but the mechanism by which this occurs remains unclear. Duke University School of Medicine researchers have now shown how CXCL10 interacts with syndecan 4 ,...
07:00 , Jun 3, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Pulmonary disease

Pulmonary disease Pulmonary fibrosis Chemokine CXC motif ligand 10 (CXCL10; IP-10); syndecan 4 (SDC4); CXC chemokine receptor 3 (CXCR3) In vitro and mouse studies suggest that a modified version of CXCL10 could be used to...
07:00 , Aug 28, 2006 |  BioCentury  |  Strategy

GSK's chemoattraction

In the Paleozoic era, small molecule drugs like methotrexate and steroids were just about the only game in town for serious autoimmune and inflammatory diseases. Then biologics became the hot thing because they represented a...
08:00 , Jan 24, 2005 |  BioCentury  |  Tools & Techniques

Unblinding the targets

ChemoCentryx Inc. has been tight-lipped about the targets of its chemokine-centered research, disclosing only the targets of its two partnered programs. The company is now ready to talk about its four proprietary programs, with all...
07:00 , Apr 5, 2004 |  BC Week In Review  |  Company News

Amgen, Tularik deal

AMGN will acquire the 79% of TLRK it does not already own for $25 per share in AMGN stock, valuing the deal at $1.3 billion based on TLRK's 52 million shares outstanding. The take-out price...